debt_leverage_profile
Minimal debt; Enlivex is essentially debt-free with ~$30M cash runway, so a 20bp rate rise has negligible P&L impact.
Inferred
Agent_Inference
interest_rate_sensitivity
Near-zero interest expense exposure; higher rates marginally improve cash yield on treasury holdings, net positive ~$60K annually.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Israel (primary R&D and manufacturing site) and U.S. FDA/EMA regulatory chokepoints for apoptotic cell therapy inputs.
Inferred
Agent_Inference
international_expansion_readiness
Revenue is pre-commercial; no material international revenue streams yet, so sovereign currency devaluation risk is minimal.
Inferred
Agent_Inference
geographic_footprint
Operations concentrated in Israel (ILS) and U.S. (USD); ILS devaluation risk is real given geopolitical tensions in the region.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Dependent on specialized GMP bioreactor and apoptotic cell processing suppliers; substitution is difficult, representing high single-vendor risk.
Inferred
Agent_Inference
business_model_type_primary
Cloud dependency is low; core operations are wet-lab and clinical-trial based with limited SaaS infrastructure reliance.
Inferred
Agent_Inference
business_model_type_secondary
Pre-revenue biotech; no cloud-hosted commercial product. AWS/GCP termination would disrupt data management but not core therapy delivery.
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; Enlivex's operations are biology-driven, not software-API-dependent.
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is grant/milestone/future licensing-based; does not resemble an investment contract under the Howey Test.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Clinical trial data subject to GDPR (EU trials) and Israeli privacy law; CCPA exposure minimal given no U.S. consumer data collection.
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; pre-commercial single-product biotech with no market share to scrutinize.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% non-recurring; revenue consists of grants and potential milestone payments, no subscription or retainer contracts.
Inferred
Agent_Inference
monetization_vector
Future monetization via licensing, partnership milestones, or product commercialization; currently grant and equity-funded.
Inferred
Agent_Inference
pricing_architecture
No commercial pricing yet; future pricing will be outcomes-based or hospital formulary-negotiated for cell therapy.
Inferred
Agent_Inference
pricing_power_rating
Potential high pricing power if Allocetra gains approval for sepsis/GvHD indications given unmet medical need and no direct competitors.
Inferred
Agent_Inference
target_gross_margin_bracket
Projected 60–75% gross margins post-commercialization, typical for advanced cell therapy biologics at scale.
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider risk; therapy is a one-time acute-care treatment, not a subscription service.
Inferred
Agent_Inference
headcount_cost_structure
Headcount-linear in clinical phase; scaling to commercialization would require significant manufacturing and sales headcount additions.
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is high in Phase II/III due to per-patient trial costs; post-approval, manufacturing scale could reduce unit costs.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Enlivex does not operate a franchise model.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC would be dominated by hospital formulary access and reimbursement negotiation costs, estimated high per account.
Inferred
Agent_Inference
network_effect_present
No network effects present; cell therapy efficacy is independent of user base size.
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk is low; core value is proprietary biological process and clinical data, not automatable functions.
Inferred
Agent_Inference
recession_resistance_tier
Moderate resilience; sepsis and GvHD are acute life-threatening conditions with inelastic treatment demand regardless of economic cycle.
Inferred
Agent_Inference
customer_segment_primary
Hospital ICUs and transplant centers treating sepsis and GvHD patients; high concentration in academic medical centers.
Inferred
Agent_Inference
customer_segment_secondary
Hematology/oncology departments for GvHD indication; small number of specialized transplant programs globally.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital is being deployed into clinical trials and GMP manufacturing scale-up; no legacy infrastructure reallocation needed.
Inferred
Agent_Inference
sec_cik
0001596812
High
SEC-EDGAR
ticker
ENLV
High
SEC-EDGAR